AMVUTTRA is an FDA-approved RNAi therapeutic for the treatment of ATTR amyloidosis, a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the nerves, heart and GI tract.
"We are delighted to acquire a royalty interest in AMVUTTRA," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "AMVUTTRA is a breakthrough RNAi therapeutic that delivers compelling benefits to patients, including a meaningful reduction in all-cause mortality for ATTR cardiomyopathy patients. Its impressive commercial trajectory underscores the significant market opportunity for the product and positions it as a highly attractive contributor to Royalty Pharma's portfolio."
AMVUTTRA received FDA approval for the treatment of TTR amyloidosis with cardiomyopathy (ATTR-CM) in 2025 and for hereditary TTR amyloidosis with polyneuropathy (hATTR-PN) in 2022. ATTR-CM represents a fast-growing category driven by new therapeutic options and improving diagnosis rates. There are approximately 30,000 hATTR-PN patients globally and more than 300,000 ATTR-CM patients globally, of which just 20% are currently diagnosed. AMVUTTRA sales reached approximately $1 billion in 2024, which represented 74% year-over-year growth, and are projected to exceed $6 billion by 2028 based on analyst consensus.
Transaction Terms
Royalty Pharma has acquired Blackstone's 1% royalty on worldwide net sales of AMVUTTRA in exchange for an upfront payment of $310 million. The royalty duration for AMVUTTRA will extend through March 2035. The transaction is expected to deliver returns consistent with Royalty Pharma's stated targets for approved products under a range of scenarios that ...
